Covidien Makes Big Play In Endovascular With $2.6 Billion ev3 Deal
This article was originally published in The Gray Sheet
Executive Summary
Covidien says its large international operations will further accelerate ev3's fast-growing neurovascular and peripheral vascular businesses following its planned $2.6 billion acquisition of the endovascular firm
You may also be interested in...
Covidien Plans April U.S. Launch Of Solitaire For Ischemic Strokes
Clot removal device gains 510(k) clearance earlier than expected, will compete with Stryker’s Merci clot retrieval system.
Covidien Plans April U.S. Launch Of Solitaire For Ischemic Strokes
Clot removal device gains 510(k) clearance earlier than expected, will compete with Stryker’s Merci clot retrieval system.
Intracranial Stenting Doesn’t Make The Cut In NIH Study
Intracranial stenting should not be a first-line treatment in most patients with narrowed brain arteries and a recent neurological event, researchers concluded in a recent study. But the data should not be viewed as a nail in the coffin to future development of intracranial stents, investigators stressed.